Other · developed by Novo Nordisk
NNC6019-0001 is an agent administered intravenously. It is being studied in transthyretin amyloid cardiomyopathy (ATTR CM).
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07207811 | Phase 3 | Transthyretin Amyloid Cardiomyopathy (ATTR CM) | Recruiting | NVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVO page.
See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVO catalysts and pipeline →